摘　要：人肺炎支原体（MP）是一种细菌性病原体，是全球公认的导致原发性非典型肺炎的主要病因。MP是一类能够在无生命培养基上生长繁殖的细菌个体和基因组都最小的病原体。它能引起人上呼吸道和下呼吸道症状，并伴随着各种各样的肺外感染及严重并发症，一旦发生耐药菌株或多重耐药菌株的感染，将更加剧这一因素的危险性。从病原生物学的方向对肺炎支原体的致病机制、诊断治疗现状和疫苗研究进展进行论述，为MP的预防控制和治疗提供基础支撑。
关键词：肺炎支原体；致病机制；黏附机制；诊断；疫苗
中图分类号：Q93　　　　　　　文献标志码：ADOI：10.3969/j.issn.1007-7146.2021.02.004

Abstract: Mycoplasma pneumoniae (MP) is a kind bacterial of human pathogen, which could cause primary atypical pneumonia in the worldwide, as well know. According its bacteria size and genome size, MP could be defined as a smaller pathogenic bacteria, which caused both upper and lower human respiratory infections. The patients infected MP are also accompanied by various extra-pulmonary infections and other different severe comorbidites. If they are infected by drug-resistant strains or multi-drug resistant strains, they are suffered from higher risk. This review systematically reviewed and analyzed the pathogenic mechanism of MP, the progress on its diagnosis, treatment and vaccine studies, which could provide some basic knowledge of its control, prevention and treatment.
Key words: Mycoplasma pneumoniae; pathogenesis; adhesion; diagnosis; vaccine
（Acta Laser Biology Sinica, 2021, 30(2): 117-122）